| Name | Title | Contact Details |
|---|
Cardiac Insight, Inc. is a privately held medical device company based in Seattle, WA. Cardiac Insight is developing advanced, body worn ECG sensing technology aimed at the early diagnosis of atrial fibrillation (AF) and other conditions. Earlier last year, the company announced a strategic collaboration with Welch Allyn, now part of the Hill-Rom family of companies, for the distribution rights of certain products and technologies offered by Cardiac Insight.
CVRx® is a private company located in Minneapolis, Minnesota. The company has developed proprietary active implantable technology for the treatment of high blood pressure, also referred to as hypertension, and heart failure. The CVRx senior management and technical team have many years of experience commercializing implantable medical devices. The company is supported by an outstanding board of directors and a world-class scientific advisory board, which includes thought leading physicians and scientists in the field of hypertension and heart failure. CVRx has developed an implantable device that is designed to treat high blood pressure and heart failure. This new device called Barostim neo™ is designed to trigger the body`s own natural blood flow regulation system to treat high blood pressure and heart failure. CVRx has a strong intellectual property foundation, which will protect this unique technology. Barostim neo is CE marked in Europe for the treatment of hypertension patients. It is also CE marked in Europe for the treatment of heart failure. This product is currently under clinical evaluation in the United States and Canada for the treatment of high blood pressure and heart failure.
CoolSystems, Inc. is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Acuson Corporation is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sirtex is a rapidly growing, profitable, global life-sciences business focused on helping medical professionals improve clinical outcomes for cancer patients through innovative and effective interventional oncology therapies.